Michael K Schultz PhD is a Co-Founder and Chief Science Officer of Perspective Therapeutics. Dr. Schultz is also Associate Professor Emeritus of Radiology and Free Radical and Radiation Biology at the University of Iowa (Iowa City, Iowa, USA). Dr. Schultz has been involved in peptide-based radiopharmaceutical research and the development of new imaging and therapy agents for cancer for over 20 years and has been a Project Leader in the Neuroendocrine Tumor Specialized Program of Research Excellence (SPORE) team at the University of Iowa since 2015. His expertise is cancer radiopharmaceutical sciences, radiochemistry, radiation biology, cancer oxidative metabolism and drug resistance, and bioconjugate chemistry with a focus on receptor targeted imaging-guided alpha-particle radionuclide therapy for cancer. His recent publications demonstrate the potential for alpha-particle targeted radionuclide therapy; 203Pb based dosimetry for 212Pb based therapeutics; production of 203Pb/212Pb radiopharmaceuticals; ligand design; and generator produced radionuclides.
